LVTX LAVA Therapeutics
- 1.110
- -0.090-7.50%
- 1.140
- +0.030+2.70%
LAVA Therapeutics News
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
LAVA Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | 20-F: FY2023 Annual Report
LAVA Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Novo Holdings A/S(0%)
LAVA Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Redmile Group, LLC(7.9%),Jeremy C. Green(7.9%), etc.
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Novo Holdings A/S(7.1%)
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
LAVA Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Novo Holdings A/S(9.13%)
LAVA Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
LAVA Therapeutics | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
LAVA Therapeutics | 20-F: FY2022 Annual Report
No Data